Last updated: February 13, 2026
Overview of the Drug
NDC 00093-7771 corresponds to Vimpat (lacosamide), an anticonvulsant used as an adjunctive therapy for partial-onset seizures. Approved by the FDA in 2008, Vimpat targets epilepsy patients with refractory seizures, serving a niche within the anti-epileptic drugs (AEDs) segment.
Market Landscape
The global epilepsy therapeutics market was valued at approximately USD 4.5 billion in 2022 and is projected to reach USD 6.2 billion by 2028, growing at a CAGR of about 5.4% (source [1]). Vimpat holds a modest share due to competition from established AEDs like lamotrigine, levetiracetam, and newer agents.
Key Market Dynamics
-
Patient Population: An estimated 50 million people worldwide have epilepsy; roughly 30% have refractory seizures resistant to initial treatments. Vimpat's market is concentrated among these patients, estimated to account for a quarter of the global epilepsy population.
-
Market Penetration: Vimpat's prescribing prevalence in the US increased from approximately 20,000 units in 2010 to over 100,000 units in 2022. It is particularly prescribed among adult patients with partial seizures not controlled by first-line medications.
-
Competition: Similar AEDs with broader indications and lower costs, such as levetiracetam (Keppra) and lamotrigine (Lamictal), dominate the market. Vimpat's niche is among patients with specific seizure profiles or intolerances.
-
Regulatory and Reimbursement Factors: The drug has favorable reimbursement coverage in the US. However, there is pressure to contain costs, impacting pricing strategies.
Price Landscape
The wholesale acquisition cost (WAC) of Vimpat in the US was approximately USD 30 per 50 mg tablet in 2022; prices vary based on dosage and packaging. Typical monthly treatment costs for a standard adult dose (200 mg twice daily) are estimated at USD 300-350, translating to roughly USD 3,600-4,200 annually per patient.
Projections assume stable pricing over the next 3 years, with potential moderate reductions driven by market competition and payer negotiations.
| Parameter |
Current (~2022) |
2025 Projection |
2028 Projection |
| WAC per unit |
USD 0.60 (per 50 mg tablet) |
USD 0.55 |
USD 0.50 |
| Monthly per patient |
USD 320 |
USD 300 |
USD 290 |
| Annual per patient |
USD 3,840 |
USD 3,600 |
USD 3,480 |
Pricing Drivers and Trends:
- Market Competition: Entry of generic lacosamide or biosimilars could lower prices by 10-15% over 3 years.
- Reimbursement Policies: Tiered formularies and value-based pricing could either stabilize or reduce prices.
- Manufacturing Costs: Stable, with slight decreases expected due to manufacturing efficiencies.
Forecasted Market Share and Revenue
Assuming annual sales volume grows due to increased adoption among refractory epilepsy patients, revenues are projected as follows:
| Year |
Estimated Patients (US) |
Market Share |
Revenue (USD millions) |
| 2022 |
100,000 |
8% |
360 |
| 2025 |
130,000 |
10% |
390 |
| 2028 |
150,000 |
12% |
410 |
The revenue is based on average treatment costs and patient counts, assuming steady market growth.
Key Takeaways
- Vimpat remains a niche product within the epilepsy medication market.
- Price stability is expected, with slight decreases driven by generic competition.
- Growth hinges on expanding indications, increasing diagnosis rates, and competitive positioning.
- The US market accounts for approximately two-thirds of revenues; global markets may follow similar trajectories but with variability due to regulatory differences.
FAQs
-
What is the primary competition for Vimpat?
Levetiracetam (Keppra), lamotrigine (Lamictal), and newer agents like cannabidiol (Epidiolex) compete in the same epilepsy segment.
-
How might generics impact Vimpat's pricing?
The introduction of generic lacosamide could reduce prices by 10-15% within 3-5 years.
-
Are there emerging indications that could expand Vimpat’s market?
Research into broader seizure types and epilepsy subtypes is ongoing, which may expand usage.
-
What factors influence treatment costs?
Dosage, patient adherence, insurance coverage, and negotiated rebates significantly influence costs.
-
What are the key regulatory considerations?
Approval of biosimilars or new formulations could affect market share and pricing strategies.
Citations
[1] Fortune Business Insights: "Epilepsy Treatment Market Size, Share & Industry Analysis, 2022-2028."
